Rayno Life Science -Biomarkers: BGMD,VRML
Biomarker MicroCap Face-Off: BGMD vs VRML Vermillion announced Q1 Results today today with OVA1 revenues of $312K of which $114 k was licensing revenues from their testing partner Quest Diagnostics Inc.(DGX $57). Operating expenses were down to $2.4M compared to$4.8M in the same period a year...
Rayno Life Science: DX and Tools Update ALR 5/11/12
More Bad News on Alere The second shoe has dropped on Alere (ALR $19) with the stock off 15% as the FDA inspection news regarding manufacturing and quality at the “Biosite”facility.Leerink Swann downgraded the stock to “Market Perform” after trying to support the stock...
Rayno Life Science Update-Macro Rules, Risk Off
Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only...
Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%
The NASDAQ Biotechnology Index IBB ($122.30) is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors to...
Alere Inc.(ALR) : Where is the bottom and what went wrong?
ALR ($21.58) Continues to Sell-off Slicing through 3 Mo. Technical Bottom We have included Alere in our diagnostics and tools portfolio since 2/2/09 at a price of $25, and although the stock is trading more than 10% under that price 3 years later, there was an opportunity to get out in the...
